H1N1 (swine) flu: Difference between revisions
ClaireLewis (talk | contribs) |
|||
| (5 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
==High-risk groups== | ==Background== | ||
===High-risk groups=== | |||
*Pregnant- increased rates of SAB, preterm labor | |||
*Chronic lung disease | |||
*Immunosuppressed | |||
*Cardiac | |||
*[[Diabetes mellitus]] | |||
==Screening== | ===Screening=== | ||
Individuals with an acute febrile respiratory illness (a measured temperature of 100ºF or higher and recent onset of at least one of the following: rhinorrhea, nasal congestion, sore throat, or cough) or sepsis-like syndrome | *Individuals with an acute febrile respiratory illness (a measured temperature of 100ºF or higher and recent onset of at least one of the following: rhinorrhea, nasal congestion, sore throat, or cough) or sepsis-like syndrome. | ||
*HIGH PRIORITY for hospitalized patients and those at high-risk for severe disease. | |||
== | ==Clinical Features== | ||
==Differential Diagnosis== | |||
Adult: 75-mg capsule twice per day for 5 days | |||
==Evaluation== | |||
*Rapid Flu nasal swab 60-80% sensitive in detecting influenza A | |||
**If patient is negative, severely ill and will be hospitalized, send viral culture | |||
*PCR is the recommended confirmatory test | |||
==Management== | |||
*Adult: [[Tamiflu]] 75-mg capsule twice per day for 5 days | |||
**All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1) | |||
**Patients who are at higher risk for seasonal influenza complications | |||
''Most effective when started within 48 hours of illness onset.'' | |||
===Post-exposure chemoprophylaxis=== | ===Post-exposure chemoprophylaxis=== | ||
*[[Tamiflu]] 75mg PO daily x 10 days (10 days after the last known exposure to novel (H1N1) influenza) | |||
''If the contact occurred with a patient after 7 days of symptom onset, then chemoprophylaxis is not necessary. This is the presumed post-infectious period.'' | |||
==Disposition== | |||
==See Also== | ==See Also== | ||
*[[Influenza]] | *[[Influenza]] | ||
==References== | |||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 00:11, 26 February 2017
Background
High-risk groups
- Pregnant- increased rates of SAB, preterm labor
- Chronic lung disease
- Immunosuppressed
- Cardiac
- Diabetes mellitus
Screening
- Individuals with an acute febrile respiratory illness (a measured temperature of 100ºF or higher and recent onset of at least one of the following: rhinorrhea, nasal congestion, sore throat, or cough) or sepsis-like syndrome.
- HIGH PRIORITY for hospitalized patients and those at high-risk for severe disease.
Clinical Features
Differential Diagnosis
Evaluation
- Rapid Flu nasal swab 60-80% sensitive in detecting influenza A
- If patient is negative, severely ill and will be hospitalized, send viral culture
- PCR is the recommended confirmatory test
Management
- Adult: Tamiflu 75-mg capsule twice per day for 5 days
- All hospitalized patients with confirmed, probable or suspected novel influenza (H1N1)
- Patients who are at higher risk for seasonal influenza complications
Most effective when started within 48 hours of illness onset.
Post-exposure chemoprophylaxis
- Tamiflu 75mg PO daily x 10 days (10 days after the last known exposure to novel (H1N1) influenza)
If the contact occurred with a patient after 7 days of symptom onset, then chemoprophylaxis is not necessary. This is the presumed post-infectious period.